{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T17:06:27Z","timestamp":1789232787754,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Grant-in-Aid for Scientific Research","award":["KAKENHI 25K11527"],"award-info":[{"award-number":["KAKENHI 25K11527"]}]},{"name":"Grant-in-Aid for Special Research from the Promotion and Mutual Aid Corporation for Private Schools of Japan."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-026-01147-w","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:10:07Z","timestamp":1782105007000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development of IgA nephropathy following risankizumab therapy for psoriatic arthritis: a case report"],"prefix":"10.1007","volume":"15","author":[{"given":"Motohiro","family":"Yagasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2282-1322","authenticated-orcid":false,"given":"Koshi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Koshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harumi","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Ogiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Kihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohito","family":"Gohda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"1147_CR1","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.kint.2017.10.019","volume":"93","author":"H Suzuki","year":"2018","unstructured":"Suzuki H, Yasutake J, Makita Y, Tanbo Y, Yamasaki K, Sofue T, et al. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. Kidney Int. 2018;93:700\u20135.","journal-title":"Kidney Int"},{"key":"1147_CR2","unstructured":"Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, Liu ZH, Roberts IS, Yuzawa Y, Zhang H, Feehally J; IgAN classification working group of the international IgA nephropathy network and the renal pathology society; Conference participants. Oxford classification of IgA nephropathy. An update from the IgA nephropathy classification working group. Kidney Int. 2016;2017(91):1014\u201321."},{"key":"1147_CR3","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","volume":"75","author":"MM Schoels","year":"2016","unstructured":"Schoels MM, Aletaha D, Alasti F, Smolen JS. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016;75:811\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1147_CR4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69:48\u201353.","journal-title":"Ann Rheum Dis"},{"key":"1147_CR5","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1681\/ASN.2011050464","volume":"22","author":"H Suzuki","year":"2011","unstructured":"Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22:1795\u2013803.","journal-title":"J Am Soc Nephrol"},{"key":"1147_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2025.151565","volume":"44","author":"J Novak","year":"2024","unstructured":"Novak J, Reily C, Steers NJ, Schumann T, Rizk DV, Julian BA, et al. Emerging biochemical and immunologic mechanisms in the pathogenesis of IgA nephropathy. Semin Nephrol. 2024;44:151565.","journal-title":"Semin Nephrol"},{"key":"1147_CR7","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.kint.2025.07.038","volume":"108","author":"L Novak","year":"2025","unstructured":"Novak L, Hall SD, Cutter G, Gurganus GL, Rizk DV, Julian BA, et al. Kidney injury and colocalization of complement C3, IgA, and IgG in glomerular immune-complex deposits of patients with IgA nephropathy or IgA vasculitis with nephritis. Kidney Int. 2025;108:1158\u201369.","journal-title":"Kidney Int"},{"key":"1147_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn7774","volume":"8","author":"X Chi","year":"2022","unstructured":"Chi X, Jin W, Zhao X, Xie T, Shao J, Bai X, et al. ROR\u03b3t expression in mature T(H)17 cells safeguards their lineage specification by inhibiting conversion to T(H)2 cells. Sci Adv. 2022;8:eabn7774.","journal-title":"Sci Adv"},{"key":"1147_CR9","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1093\/ndt\/gfq325","volume":"25","author":"K Yamada","year":"2010","unstructured":"Yamada K, Kobayashi N, Ikeda T, Suzuki Y, Tsuge T, Horikoshi S, et al. Down-regulation of core 1 \u03b21,3-galactosyltransferase and Cosmc by Th2 cytokine alters O-glycosylation of IgA1. Nephrol Dial Transplant. 2010;25:3890\u20137.","journal-title":"Nephrol Dial Transplant"},{"key":"1147_CR10","doi-asserted-by":"publisher","first-page":"5330","DOI":"10.1074\/jbc.M113.512277","volume":"289","author":"H Suzuki","year":"2014","unstructured":"Suzuki H, Raska M, Yamada K, Moldoveanu Z, Julian BA, Wyatt RJ, et al. Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes. J Biol Chem. 2014;289:5330\u20139.","journal-title":"J Biol Chem"},{"key":"1147_CR11","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1056\/NEJMoa2510198","volume":"394","author":"R Lafayette","year":"2026","unstructured":"Lafayette R, Barbour SJ, Brenner RM, Campbell KN, Doan T, Eren N, et al. A phase 3 trial of atacicept in patients with IgA nephropathy. N Engl J Med. 2026;394:647\u201357.","journal-title":"N Engl J Med"},{"key":"1147_CR12","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMoa2512133","volume":"394","author":"V Perkovic","year":"2026","unstructured":"Perkovic V, Trimarchi H, Tesar V, Lafayette R, Wong MG, Barratt J, et al. Sibeprenlimab in IgA nephropathy\u2014interim analysis of a phase 3 trial. N Engl J Med. 2026;394:635\u201346.","journal-title":"N Engl J Med"},{"key":"1147_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1169735","volume":"14","author":"Y Shu","year":"2023","unstructured":"Shu Y, Chen J, Ding Y, Zhang Q. Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system. Front Immunol. 2023;14:1169735.","journal-title":"Front Immunol"},{"key":"1147_CR14","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000000462","volume":"7","author":"T Strobel","year":"2020","unstructured":"Strobel T, Ahmed W, De la Sancha C, Bohm M, Fischer M. IgA nephropathy in the setting of anti-TNF-\u03b1 therapy for inflammatory bowel disease. ACG Case Rep J. 2020;7:e00462.","journal-title":"ACG Case Rep J"},{"key":"1147_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s13730-023-00836-0","volume":"13","author":"A Shimizu","year":"2024","unstructured":"Shimizu A, Tsuboi N, Haruhara K, Shirai I, Ogawa K, Miura A, et al. Active flare of IgA nephropathy during long-term therapy with anti\u2013tumor necrosis factor-\u03b1 antibody drugs for Crohn\u2019s disease: three case reports and literature review. CEN Case Reports. 2024;13:249\u201357.","journal-title":"CEN Case Reports"},{"key":"1147_CR16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s13730-020-00457-x","volume":"9","author":"N Kanazawa","year":"2020","unstructured":"Kanazawa N, Wada Y, Akiyama M, Shikida Y, Sugiyama M, Abe M, et al. Crescentic IgA nephropathy after administration of human monoclonal interleukin-12\/23p40 antibody in a patient with Crohn\u2019s disease: a case report. CEN Case Rep. 2020;9:204\u20139.","journal-title":"CEN Case Rep"},{"key":"1147_CR17","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000001437","volume":"11","author":"C Larson","year":"2024","unstructured":"Larson C, Munir N, Rao P, Farkash E, Kathuria P, Romain D, et al. Crohn\u2019s disease associated with IgA nephropathy effectively treated with the interleukin-23 inhibitor risankizumab. ACG Case Rep J. 2024;11:e01437.","journal-title":"ACG Case Rep. J."},{"key":"1147_CR18","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.kint.2025.04.003","volume":"108","author":"J Floege","year":"2025","unstructured":"Floege J, Barratt J, Cook HT, Noronha IL, Reich HN, Suzuki Y, et al. Executive summary of the KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV). Kidney Int. 2025;108:548\u201354.","journal-title":"Kidney Int"},{"key":"1147_CR19","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1093\/ndt\/15.8.1146","volume":"15","author":"F Nogaki","year":"2000","unstructured":"Nogaki F, Muso E, Kobayashi I, Kusano H, Shirakawa K, Kamata T, et al. Interleukin 12 induces crescentic glomerular lesions in a high IgA strain of ddY mice, independently of changes in IgA deposition. Nephrol Dial Transplant. 2000;15:1146\u201354.","journal-title":"Nephrol Dial Transplant"},{"key":"1147_CR20","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.4049\/jimmunol.159.5.2327","volume":"159","author":"SR Chintalacharuvu","year":"1997","unstructured":"Chintalacharuvu SR, Emancipator SN. The glycosylation of IgA produced by murine B cells is altered by Th2 cytokines. J Immunol. 1997;159:2327\u201333.","journal-title":"J Immunol"},{"key":"1147_CR21","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1046\/j.1365-2249.2001.01678.x","volume":"126","author":"SR Chintalacharuvu","year":"2001","unstructured":"Chintalacharuvu SR, Nagy NU, Sigmund N, Nedrud JG, Amm ME, Emancipator SN. T cell cytokines determine the severity of experimental IgA nephropathy by regulating IgA glycosylation. Clin Exp Immunol. 2001;126:326\u201333.","journal-title":"Clin Exp Immunol"},{"key":"1147_CR22","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1159\/000505748","volume":"6","author":"K Yamada","year":"2020","unstructured":"Yamada K, Huang ZQ, Raska M, Reily C, Anderson JC, Suzuki H, et al. Leukemia inhibitory factor signaling enhances production of galactose-deficient IgA1 in IgA nephropathy. Kidney Dis. 2020;6:168\u201380.","journal-title":"Kidney Dis"},{"key":"1147_CR23","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.ekir.2023.11.003","volume":"9","author":"K Yamada","year":"2023","unstructured":"Yamada K, Huang ZQ, Reily C, Green TJ, Suzuki H, Novak J, et al. LIF\/JAK2\/STAT1 signaling enhances production of galactose-deficient IgA1 by IgA1-producing cell lines derived from tonsils of patients with IgA nephropathy. Kidney Int Rep. 2023;9:423\u201335.","journal-title":"Kidney Int Rep"},{"key":"1147_CR24","doi-asserted-by":"crossref","unstructured":"Dand N, Stuart PE, Bowes J, Ellinghaus D, Nititham J, Saklatvala JR, Teder-Laving M, Thomas LF, Traks T, Uebe S, Assmann G, Baudry D, Behrens F, Billi AC, Brown MA, Burkhardt H, Capon F, Chung R, Curtis CJ, Duckworth M, Ellinghaus E, FitzGerald O, Gerdes S, Griffiths CEM, Gulliver S, Helliwell PS, Ho P, Hoffmann P, Holmen OL, Huang ZM, Hveem K, Jadon D, K\u00f6hm M, Kraus C, Lamacchia C, Lee SH, Ma F, Mahil SK, McHugh N, McManus R, Modalsli EH, Nissen MJ, N\u00f6then M, Oji V, Oksenberg JR, Patrick MT, Perez White BE, Ramming A, Rech J, Rosen C, Sarkar MK, Schett G, Schmidt B, Tejasvi T, Traupe H, Voorhees JJ, Wacker EM, Warren RB, Wasikowski R, Weidinger S, Wen X, Zhang Z; BSTOP study group; Estonian Biobank research team; Barton A, Chandran V, Esko T, Foerster J, Franke A, Gladman DD, Gudjonsson JE, Gulliver W, H\u00fcffmeier U, Kingo K, K\u00f5ks S, Liao W, L\u00f8set M, M\u00e4gi R, Nair RP, Rahman P, Reis A, Smith CH, Di Meglio P, Barker JN, Tsoi LC, Simpson MA, Elder JT. GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets. Nat Commun. 2025;16:2051.","DOI":"10.1038\/s41467-025-56719-8"},{"key":"1147_CR25","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/s41588-023-01422-x","volume":"55","author":"K Kiryluk","year":"2023","unstructured":"Kiryluk K, Sanchez-Rodriguez E, Zhou XJ, Zanoni F, Liu L, Mladkova N, et al. Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy. Nat Genet. 2023;55:1091\u2013105.","journal-title":"Nat Genet"},{"key":"1147_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10123027","author":"T Kano","year":"2022","unstructured":"Kano T, Suzuki H, Makita Y, Nihei Y, Fukao Y, Nakayama M, et al. Mucosal immune system dysregulation in the pathogenesis of IgA nephropathy. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10123027.","journal-title":"Biomedicines"},{"key":"1147_CR27","doi-asserted-by":"publisher","first-page":"1737992","DOI":"10.3389\/fimmu.2026.1737992","volume":"17","author":"K Yamada","year":"2026","unstructured":"Yamada K, Ogiwara K, Novak J, Suzuki Y. Aberrant signaling in tonsillar B cells producing pathogenic O-glycoforms of IgA1 in IgA nephropathy. Front Immunol. 2026;17:1737992.","journal-title":"Front Immunol"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-026-01147-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-026-01147-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-026-01147-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T05:10:11Z","timestamp":1782105011000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-026-01147-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["1147"],"URL":"https:\/\/doi.org\/10.1007\/s13730-026-01147-w","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"14 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted according to the Declaration of Helsinki guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed and written signed consent was provided by the patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"103"}}